Form 4: Lexicon Pharmaceuticals SVP, CFO Scott M. Coiante Reports Stock Option and Restricted Stock Unit Grants

Scott M. Coiante, SVP and CFO of Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• On February 13, 2025, Scott M. Coiante, the SVP and CFO of Lexicon Pharmaceuticals, reported the acquisition of 721,070 stock options and 480,710 restricted stock units (RSUs).
• The stock options have an exercise price of $0.695 and expire on February 13, 2035.
• The options vest 25% on the first anniversary of the grant date and then 1/48th per month thereafter.
• The RSUs vest in three equal installments on February 28 of each of the three years following the grant year.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of executive compensation, which is generally viewed neutrally. The equity grants are a positive sign of aligning management interests with shareholders.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize long-term performance and retention.

Industry Context

This type of equity compensation is standard practice for publicly traded companies to incentivize executives.

Comparison to Industry Standards

• Equity grants are a common component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options and RSUs to align executive incentives with shareholder value.
• The vesting schedules described are fairly standard, with multi-year vesting periods being typical.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of aligning management interests with long-term company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates